Trial Outcomes & Findings for Sensory Habituation in Autism Spectrum Disorders (NCT NCT06247176)

NCT ID: NCT06247176

Last Updated: 2026-05-29

Results Overview

This will be the change in the bold response as measured by the fMRI scan.

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

1 participants

Primary outcome timeframe

There are two 1 hour sessions in which the bold response will be measured. The first time point will be during visit 2 of the study. The second time point will be the final visit of the study.

Results posted on

2026-05-29

Participant Flow

Participant milestones

Participant milestones
Measure
Autism Spectrum Disorder Habituation Group
This will be the group of subjects with Autism and sensory over-responsivity. This group will go through a mock-MRI, a pre-habituation MRI, the habituation protocol in virtual reality, and a post-habituation MRI.
Neurotypical Habitation Group
This will be the group of subjects who are neurotypical peers. This group will go through a mock-MRI, a pre-habituation MRI, the habituation protocol in virtual reality, and a post-habituation MRI.
Overall Study
STARTED
1
0
Overall Study
COMPLETED
1
0
Overall Study
NOT COMPLETED
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Sensory Habituation in Autism Spectrum Disorders

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Autism Spectrum Disorder Habituation Group
n=1 Participants
This will be the group of subjects with Autism and sensory over-responsivity. This group will go through a mock-MRI, a pre-habituation MRI, the habituation protocol in virtual reality, and a post-habituation MRI.
Neurotypical Habitation Group
This will be the group of subjects who are neurotypical peers. This group will go through a mock-MRI, a pre-habituation MRI, the habituation protocol in virtual reality, and a post-habituation MRI.
Total
n=1 Participants
Total of all reporting groups
Age, Categorical
<=18 years
1 Participants
n=51 Participants
0 Participants
n=14 Participants
1 Participants
n=65 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=51 Participants
0 Participants
n=14 Participants
0 Participants
n=65 Participants
Age, Categorical
>=65 years
0 Participants
n=51 Participants
0 Participants
n=14 Participants
0 Participants
n=65 Participants
Sex: Female, Male
Female
0 Participants
n=51 Participants
0 Participants
n=14 Participants
0 Participants
n=65 Participants
Sex: Female, Male
Male
1 Participants
n=51 Participants
0 Participants
n=14 Participants
1 Participants
n=65 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=51 Participants
0 Participants
n=14 Participants
0 Participants
n=65 Participants
Race (NIH/OMB)
Asian
0 Participants
n=51 Participants
0 Participants
n=14 Participants
0 Participants
n=65 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=51 Participants
0 Participants
n=14 Participants
0 Participants
n=65 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=51 Participants
0 Participants
n=14 Participants
0 Participants
n=65 Participants
Race (NIH/OMB)
White
1 Participants
n=51 Participants
0 Participants
n=14 Participants
1 Participants
n=65 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=51 Participants
0 Participants
n=14 Participants
0 Participants
n=65 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=51 Participants
0 Participants
n=14 Participants
0 Participants
n=65 Participants
Handedness
Right Handed
1 Participants
n=51 Participants
1 Participants
n=65 Participants
Handedness
Left Handed
0 Participants
n=51 Participants
0 Participants
n=65 Participants

PRIMARY outcome

Timeframe: There are two 1 hour sessions in which the bold response will be measured. The first time point will be during visit 2 of the study. The second time point will be the final visit of the study.

Population: Project was terminated before full scale analysis was performed.

This will be the change in the bold response as measured by the fMRI scan.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Galvanic skin response will be measured at 3 - 5 time points, ranging from 1 hour and 30 minutes to 3 hours and 30 minutes of data. 15 minutes will be measured at the 2nd and last visit. 1 hour will be collected at each VR visit.

Population: Project was terminated before full scale analysis was performed.

Galvanic skin response is a measure of how sweaty the skin is and can be used as a measure of the body's stress. We will look at this before during and after the habituation protocol to measure how the body adapts to the sensory stimulation.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Skin temperature will be measured at 1 - 3 time points, ranging from 1 hour to 3 hours of data. 1 hour will be collected at each VR visit.

Population: Project was terminated before full scale analysis was performed.

This will look at the change in the skins temperature before, during, and after the sensory habituation protocol. This is a measure of the body's response to a stressor.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Heart rate will be measured at 3 - 5 time points, ranging from 1 hour and 30 minutes to 3 hours and 30 minutes of data. 15 minutes will be measured at the 2nd and last visit. 1 hour will be collected at each VR visit.

Population: Project was terminated before full scale analysis was performed.

Changes in heart rate can give an indication of stress and habituation. This will be recorded before, during, and after the habituation protocol to assess how the body reacts.

Outcome measures

Outcome data not reported

Adverse Events

Autism Spectrum Disorder Habituation Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Neurotypical Habitation Group

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

James Gehringer

University of Nebraska Medical Center

Phone: 4025592562

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place